ATLANTA, Aug. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announces that Chief Executive Officer Dr.Robert McNally and Chief Financial Officer Mark Reynolds will be presenting at the 2010 Southern California Investor Conference on Tuesday, August 17. The GeoVax presentation will take place at 3:00 pm at The Island Hotel in Newport Beach, California.
Hosted by California Equity Research, LLC and sponsored by Global Hunter Securities, Brinson Patrick and Silicon Valley Bank, the Southern California Investor Conference is open to the public and provides a forum for senior management to meet current and potential investors. GeoVax is one of approximately 30 healthcare companies to be presenting at this year’s conference.
Dr.McNally said, “Meeting with potential investors in person gives us the chance to deliver the Company’s message in a uniquely powerful way. We believe that West Coast investors will be extremely interested to hear about our innovative HIV vaccine program and how we intend to maximize its market potential within the healthcare space.”
A webcast of the GeoVax presentation will be accessible via the following link:
http://events.powerstream.net/002/00271/20100817_SCIC_T3/
About The Southern California Investor Conference
The Southern California Investor Conference is open to the public and will feature presentations from the senior management of leading companies not only from Southern California but also around the country. Conference attendance includes the entire day of presentations, gourmet luncheon, free copy of California Stock Report and more. The conference is sponsored by Global Hunter Securities, Brinson Patrick, Silicon Valley Bank, and Allen & Caron, Inc. For more information visit http://www.californiastocks.com/root/socal/Home/tabid/165/Default.aspx or call (866) 928-2600.
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines’ safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax’s Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.
Forward-Looking Statements
Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax’s filings with the Securities and Exchange Commission including those set forth at “Risk Factors” in GeoVax’s Form 10-K.
Contact | |
At The Investor Relations Group: | |
Investor Relations | |
James Carbonara | |
or | |
Public Relations | |
Janet Vasquez / Robin O’Malley | |
(212) 825-3210 | |
SOURCE GeoVax Labs, Inc.
